Non-specific inhibitors to influenza virus haemagglutination in sheep serum. by Brian Ogilvie

Cover of: Non-specific inhibitors to influenza virus haemagglutination in sheep serum. | Brian Ogilvie

Published .

Written in English

Read online

Edition Notes

Book details

ContributionsManchester Polytechnic. Department of Biological Sciences.
ID Numbers
Open LibraryOL13829834M

Download Non-specific inhibitors to influenza virus haemagglutination in sheep serum.

The presence of non-specific inhibitors in immune influenza sera may falsify the antibody pattern as shown by the haemagglutination-inhibition test, and it is consequently often necessary to pre-treat sera in order to inactivate these inhibitors.

A number of different methods are in use for this by: Non-specific inhibition of haemagglutination can be demonstrated in tests with strain Bel. (D phase) of influenza virus and normal rabbit serum to titres of Such non-specific effects present obvious difficulties in interpreting by: All sera contained normal inhibitors active against at least some of the virus strains.

Removal of inhibitors from each serum by (a) heating at 56 °C. for 30 minutes, (b) receptor-destroying enzyme (e) potassium periodate, (d) trypsin trypsin Subject Category: Chemicals and Chemical GroupsCited by: An investigation of the content of non-specific inhibitors of influenza virus haemagglutination in various normal animal Non-specific inhibitors to influenza virus haemagglutination in sheep serum.

book has been carried out with the A/Eng/1/51 strain, which was used both before and after adaptation to mice in order to detect the inhibitor described by CHU [this Bulletin,v. 27, ], and with the Crawley strain of B-type virus in order to detect Francis by: 4.

VIROL () Inhibition of Influenza Virus Haemagglutination: A Difference of Behavior in Sera from a Single Species A. COHEN, S. NEWLAND, AND F. BIDDLE Department of Bacteriology, University College Hospital Medical School, University Street, London, England Accepted April 1, Two t3rpes of horse serum are described which differ in the patterns of inhibitory activity Cited by: Human colostrum contains a non-specific inhibitor of influenza virus haemagglutination, whose activity is mediated by the N-acetylneuraminic acid substituent groups of a S glycoprotein.

It is suggested that this inhibitor has a fourfold greater T-chain content than that observed in rabbit colostral by: 7.

Influenza viruses have a high potential for genetic and antigenic diversity, and influenza epidemiology is characterized by regular epidemics of antigenically distinct strains. 17 Since the binding region of the HA1 protein is a key target for neutralising antibodies, it is under intense immune-mediated positive selection pressure, resulting in the acquisition and retention of amino acid substitutions that favor Cited by: The intranasal inoculation of volunteers with living partially attenuated strains of influenza A and B viruses offers a new opportunity to determine the protective effect of serum haemagglutin-inhibiting antibody against a strictly homologous virus, under conditions where the time and dosage of the infective challenge can be controlled, the scoring of proven infections can be more precise and higher rates of infection Cited by: Styk, B.: Effect of some inhibitor-destroying substances on the non-specific inhibitor of C influenza virus present in normal rat serum.

Acta virol. Acta virol. 7, 88–89 ().Cited by: Haemagglutination-inhibiting antibody to influenza virus. The results of the haemagglutination-inhibiting (HI) antibody test for influenza virus antibody in human sera closely match those produced by virus neutralization assays and are predictive of protection.

The hemagglutination inhibition assay (HAI) is widely used to evaluate vaccine-induced antibody responses as well as to antigenically characterize influenza viruses.

The results of an HAI assay are based on an endpoint titration where the titers are generally manually interpreted and recorded by a well-trained expert. For serological applications, the lack of standardization in endpoint Cited by: 6.

The influenza virus is the causative agent of flu infection. Currently there are four drugs in use to combat influenza infection. Amantadine and rimantadine are M2 proton channel blockers that inhibit virus uncoating; oseltamivir and zanamivir are neuraminidase (NA) inhibitors that inhibit virus release.

Both antisera and non-specific inhibitors of haemagglutination have been shown to flocculate influenza virus particles [this Bulletin,v. 31, ;v. 32, ]. Now γinhibitor has been shown to flocculate purified inhibitor-sensitive influenza A2 virus macroscopically in Dreyer's tubes even when the partially purified inhibitor was diluted I in Cited by: 9.

Serum is pre-treated to remove non-specific haemagglutinins and inhibitors. A viral haemagglutinin preparation that produces visible haemagglutination (usually 4 haemagglutination units) is then pre-incubated with two-fold dilutions of the serum specimen.

The lowest dilution of serum that inhibits haemagglutination is the HI titre. detectable HI activity with influenza A (H3N2), (H1N1) and b viruses (see appendix). Before use in HI tests, non-specific inhibitors should be removed from antiserum reagent 00/ by normal procedures.

Antiserum reagent 00/ may be used for SRD assay of influenza H5 HA antigens. The non-specific serum inhibitor of rubella virus HA has been identified as a beta-lipoprotein (Sedwick, Furukawa and Plotkin, ), and Stastny and Hoi'ejgi () have reported that beta.

Human serum may contain three inhibitors of influenza virus haemagglutination, namely antibody, an agent which inhibits unheated influenza virus (" non-specific inhibitor") and one, the " Francis inhibitor", which inhibits haemagglutination by heated influenza B (Lee) virus.

The first is present only in immune sera; the second and third in both immune and normal by: Isolation and characterization of influenza C virus inhibitors in rat serum Fumio Kitame*, Kiyoto Nakamura*, Akio Saitot, Hyogo Sinoharat and Morio Homma~ Two inhibitors against haemagglutination by influenza C virus were isolated from pooled sera of normal rats by sequential chromatography on Blue Sepharose CL 6IR Ultrogel and DEAE-ceHuios~ The two inhibitors Cited by: 1.

Convalescent levels of antibody against either type A or B influenza virus were demonstrated in human sera. Positive but inconsistent results were obtained with swine sera. The antigens used in the AGP test are non-infectious and stable.

The test is easy and economical to by: It is hoped that this work will fulfil this purpose in the case of the influenza viruses. The work is primarily intended for the virologist, and the clinical, pathological and epidemiological aspects of influenza are dealt with only in so far as they relate to the properties of the viruses.


SHORTRIDGE* and G. BELYAVIN Department of'BacterioloU, University College Hospital Medical School, London WCIEEngland INTRODUCTION Two closely related antigenically Cited by: 1.

influenza virus field isolates. The HA protein on the surface of influenza virus agglutinates erythrocytes.

Specific attachment of antibody to the antigenic sites on the HA molecule interferes with the binding between the viral HA and receptors on the erythrocytes. This effect inhibits haemagglutination and is the basis for the HAI. The hemagglutination assay or haemagglutination assay (HA) and the hemagglutination inhibition assay (HI or HAI) were developed in –42 by American virologist George Hirst as methods for quantifying the relative concentration of viruses, bacteria, or antibodies.

HA and HI apply the process of hemagglutination, in which sialic acid receptors on the surface of red blood cells (RBCs) bind. Request PDF | Hemagglutinin Inhibition Assay with Swine Sera | Hemagglutination is based on the ability of viruses such as influenza A virus to agglutinate red blood cells (RBCs) of specific.

After incubation, the HI titer is read as the highest dilution of serum that inhibits hemagglutination. A fourfold or greater increase in HI antibody titer is regarded as evidence of infection.Hemagglutination inhibition antibodies define subtype-specific antigens on the virus particle.

The hemagglutination inhibition (HAI) assay quantifies the level of strain-specific influenza virus antibody present in serum and is the standard by which influenza vaccine immunogenicity is measured.

non‐specific inhibitors of viral haemagglutination and naturally occurring agglutinins of the erythrocytes. Therefore, false‐positive or ‐negative results may arise if the sera are not treated before use (Truelove et al., ).

Enzyme‐linked immunosorbent assay (ELISA) is another option widely used for serological diagnosis of. Sample A causes hemagglutination up to the dilution; therefore the HA titer of this virus stock is The sample in row B contains no detectable virus, while that in row D has an HA titer of The HA assay can be easily modified to determine the level of antibodies to influenza virus present in serum samples.

A serum survey for antibody to two strains of influenza B virus was carried out comparing haemagglutination-inhibition (HI) and single-radial haemolysis (SRH) tests. The. The hemagglutination assay (HA) is a tool used to screen cell culture isolates or amnioallantoic fluid harvested from embryonated chicken eggs for hemagglutinating agents, such as type A influenza.

The HA assay is not an identification assay, as Cited by: Quantitation and analysis of the specificity of post-immunization antibodies to influenza B viruses using single radial haemolysis Hyperimmune sera were prepared by immunizing sheep or rabbits with influenza B virus HA enzymically released from purified virus using bromelain enzyme Serum samples were analysed by immunodouble diffusion Cited by:   Prior to evaluation of immunity toward influenza virus, serum samples are treated to remove innate inhibitors.

This treatment typically involves RDE to inactivate α and γ inhibitors and heating at 56°C to inactivate β by: Obtain a preparation of virus (e.g. influenza viruses) with known HA titer or determine its HA titer Prepare two-fold dilutions of patient/test serum to be tested e.g.

from to Add a fixed amount of virus to every well of a well plate, equivalent to 4 HA units (varies according to the virus), except for the serum control wells.

Influenza hemagglutinin (HA) or haemagglutinin [p] (British English) is a homotrimeric glycoprotein found on the surface of influenza viruses and is integral to its infectivity. Hemagglutinin is a Class I Fusion Protein, having multifunctional activity as both an attachment factor and membrane fusion ore, HA is responsible for binding Influenza virus to sialic acid on the InterPro: IPR Antibodies against spike proteins of influenza are used as a tool for characterization of viruses and therapeutic approaches.

However, development, production and quality control of antibodies is expensive and time consuming. To circumvent these difficulties, three peptides were derived from complementarity determining regions of an antibody heavy chain against influenza A spike by: 9.

Antibodies directed against haemagglutinin, measured by the haemagglutination inhibition (HI) assay are essential to protective immunity against influenza infection. An HI titre of is generally accepted to correspond to a 50% reduction in the risk of contracting influenza in a susceptible population, but limited attempts have been made to further quantify the association between HI titre Cited by:   Influenza A virus (IAV) membrane proteins hemagglutinin (HA) and neuraminidase (NA) are determinants of virus infectivity, transmissibility, pathogenicity, host Cited by:   Canine Influenza A virus subtype H3N8 (H3N8 CIV) was recognized in as a novel respiratory pathogen for dogs.

To date, infections have been diagnosed in thousands of dogs in 38 U.S. states. Diagnostic techniques such as reverse transcription polymerase chain reaction (RT-PCR) and virus isolation may yield false-negative results if samples are collected after virus shedding has by: Understanding host antibody response is crucial for predicting disease severity and for vaccine development.

We investigated antibody responses against influenza A(H7N9) virus in 48 serum samples from 21 patients, including paired samples from 15 patients. IgG against subtype H7 and neutralizing antibodies (NAbs) were not detected in acute-phase samples, but ELISA geometric mean. 1 INTRODUCTION.

Influenza viruses are single‐stranded, negative sense, segmented RNA viruses belonging to the Orthomyxoviridae family. Influenza viruses are divided into four types (A, B, C, and D) depending on their antigenic differences in the matrix and nucleoprotein (Kapoor & Dhama, ).Influenza A virus (IAV) and influenza B virus (IBV) are characterized by eight genomic Cited by: 3.

The haemagglutination-inhibition (HAI) assay is sensitive, specific, simple, inexpensive and rapid. The reference sera are usually obtained commercially and have been treated to remove any non-specific agglutinins as well as any non-specific inhibitors, both of which could interfere with the test results.

Titration of haemagglutinating virus.Moisa, I. Sensitivity of hemagglutinins of some influenza viruses to non-specific inhibitors from the serum of various species of animals. Stud. Cercet. Virusol.23, – [Google Scholar] Shortridge, K.F.; Lansdell, A. Serum inhibitors of A 2 -Hong Kong influenza virus haemagglutination.

Microbios6, –Cited by: 1.Latest Activity; Mark Channels Read; Calendar; Forum; Welcome to the SCIENTIFIC LIBRARY: COVID, SARS-CoV-2; Other scientific studies including seasonal & novel flu.

49645 views Tuesday, November 3, 2020